2022
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regression
2020
Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer
Hysell K, Yusuf R, Barakat L, Virata M, Gan G, Deng Y, Perez-Irizarry J, Vega T, Goldberg SB, Emu B. Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer. Clinical Lung Cancer 2020, 22: e498-e505. PMID: 33468393, PMCID: PMC8169710, DOI: 10.1016/j.cllc.2020.11.006.Peer-Reviewed Original ResearchConceptsCell lung cancerGeneral patientsNSCLC populationLung cancerCox proportional hazards modelYale-New Haven HospitalGeneral NSCLC populationOutcomes of patientsOverall median survivalRetrospective cohort studyPredictors of survivalKaplan-Meier curvesHIV-1 RNACopies/mLLog-rank testProportional hazards modelNew Haven HospitalCancer treatment regimensMedian CD4Antiretroviral therapyCohort studyMedian survivalOverall survivalHIV infectionMedian ageSubstantial gap in primary care: older adults with HIV presenting late to care
Yasin F, Rizk C, Taylor B, Barakat LA. Substantial gap in primary care: older adults with HIV presenting late to care. BMC Geriatrics 2020, 20: 438. PMID: 33129258, PMCID: PMC7603686, DOI: 10.1186/s12877-020-01842-y.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCombination antiretroviral therapyViral suppressionCART initiationHIV clinicOlder patientsRetrospective medical record reviewHIV viral suppressionMedical record reviewPatient demographic dataSerious public health concernPublic health concernAntiretroviral therapyCD4 countHIV testingRecord reviewImmunodeficiency virusPrimary careOlder adult groupTreatment strategiesNew diagnosisAdvanced stagePatientsDemographic dataAdult group
2019
Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals
Sopeyin A, Zhou L, Li M, Barakat L, Paintsil E. Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals. PLOS ONE 2019, 14: e0226573. PMID: 31846498, PMCID: PMC6917281, DOI: 10.1371/journal.pone.0226573.Peer-Reviewed Original ResearchConceptsTreatment-experienced individualsAntiretroviral therapyCholesterol biosynthesis genesSide effectsEffect of ARTLow density lipoprotein receptor pathwayHIV viral suppressionCase-control studyLipoprotein receptor pathwaySterol regulatory element-binding protein 2Cassette transporter A1Protein expression levelsViral suppressionLipid abnormalitiesClinical manifestationsMetabolic derangementsCardiovascular diseaseRetrospective analysisTherapeutic benefitProtein 2 geneMRNA expressionReceptor pathwayMarked decreaseDysregulationExpression levels
2018
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV-1 infectionDolutegravir/rilpivirineAntiretroviral therapyImportant drug-drug interactionsClinical trial efficacyDrug-drug interactionsImproved safety profileLong-term toxicityDrug package insertsRegimen simplificationMaintenance therapyCombination regimensMedication adherenceSafety profileSafety dataTrial efficacyConference abstractsPackage insertsDrug AdministrationUS FoodPharmacokinetic propertiesGoogle ScholarInfectionLimited dataRilpivirine
2016
Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’
Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi’s sarcoma immune reconstitution inflammatory syndrome: ‘Where a good intention turns bad’. International Journal Of STD & AIDS 2016, 27: 1026-1029. PMID: 26769754, DOI: 10.1177/0956462415627735.Peer-Reviewed Case Reports and Technical NotesConceptsImmune reconstitution inflammatory syndromeReconstitution inflammatory syndromeKS-IRISInflammatory syndromeKaposi's sarcomaKS lesionsSkin lesionsKaposi's sarcoma immune reconstitution inflammatory syndromeFull virologic suppressionNeck skin lesionsParadoxical worseningVirologic suppressionAntiretroviral therapyInitial presentationImmunodeficiency syndromeSteroid useClinician awarenessFacial lesionsLesionsSyndromeSarcomaGlucocorticoidsSteroidsCase discussionChemotherapy
2015
Comparing clinical outcomes in HIV‐infected and uninfected older men hospitalized with community‐acquired pneumonia
Barakat LA, Juthani-Mehta M, Allore H, Trentalange M, Tate J, Rimland D, Pisani M, Akgün KM, Goetz MB, Butt AA, Rodriguez-Barradas M, Duggal M, Crothers K, Justice AC, Quagliarello VJ. Comparing clinical outcomes in HIV‐infected and uninfected older men hospitalized with community‐acquired pneumonia. HIV Medicine 2015, 16: 421-430. PMID: 25959543, PMCID: PMC5015437, DOI: 10.1111/hiv.12244.Peer-Reviewed Original ResearchConceptsCommunity-acquired pneumoniaVeterans Aging Cohort StudyVACS IndexCAP outcomesAntiretroviral therapyOlder adultsHigher VACS indexDays of dischargeAging Cohort StudyUninfected participantsCohort studyMean LOSHIV infectionLonger LOSClinical outcomesUnadjusted analysesUninfected groupMultivariable modelEligibility criteriaHIVMale veteransMortality rateART useMortalityOutcomesIncreased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers
Walker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, Barakat L, Francis J, Fisher A, Kozal M, Zapata H, Shaw A, Lifton R, Sutton RE, Fikrig E. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. Journal Of Virology 2015, 89: 5502-5514. PMID: 25740989, PMCID: PMC4442529, DOI: 10.1128/jvi.00118-15.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesCD4-Positive T-LymphocytesChemokine CCL3Chemokine CCL4Chemokine CCL5Chemokines, CCCohort StudiesFemaleGene DosageHIV InfectionsHIV Long-Term SurvivorsHIV-1Host-Pathogen InteractionsHumansMacrophage Inflammatory ProteinsMaleMiddle AgedReceptors, CCR5Receptors, CXCR4RNA, MessengerUp-RegulationConceptsElite controllersHIV-seropositive individualsAntiretroviral therapyT cellsMIP-1βMIP-1αHIV infectionSeropositive individualsAbsence of ARTR5-tropic HIV-1Macrophage inflammatory protein-1αR5-tropic HIVInflammatory protein-1αT cell resistancePandemic health problemRANTES chemokinesHIV replicationRare patientsHealthy controlsTherapeutic effectHIV entryHIV-1X4-tropicHealth problemsProtein-1α
2014
Antiretroviral Therapy–Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase‐γ Inhibition
Selvaraj S, Ghebremichael M, Li M, Foli Y, Langs-Barlow A, Ogbuagu A, Barakat L, Tubridy E, Edifor R, Lam W, Cheng Y, Paintsil E. Antiretroviral Therapy–Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase‐γ Inhibition. Clinical Pharmacology & Therapeutics 2014, 96: 110-120. PMID: 24637942, PMCID: PMC4065195, DOI: 10.1038/clpt.2014.64.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsATP-Binding Cassette TransportersCase-Control StudiesDeoxyribonucleotidesDNA Polymerase gammaDNA, MitochondrialDNA-Directed DNA PolymeraseFemaleGene DosageHIV InfectionsHumansMaleMiddle AgedMitochondriaNucleic Acid Synthesis InhibitorsNucleotide Transport ProteinsNucleotidesReverse Transcriptase InhibitorsRibonucleotidesConceptsAntiretroviral therapyPeripheral blood mononuclear cellsMitochondrial toxicityBlood mononuclear cellsNegative controlMitochondrial DNA copy numberMononuclear cellsDNA copy numberMitochondrial dysfunctionHigh expression levelsPotential mechanismsGroup differencesExpression levelsPositive controlTherapyMedian valueToxicityDeoxyribonucleotide poolsCellular kinasesCassette proteinCellsDysfunctionTriphosphateControl